RadiusXR announces the publication of its NOVA Clinical Trial in Translational Vision Science and Technology (TVST), a journal by the Association for Research in Vision and Ophthalmology (ARVO). RadiusXr offers a portable vision diagnostic and patient engagement system combines medical-grade diagnostics, business management and patient education tools in a proprietary wearable XR headset. The NOVA Clinical Trial revealed statistical non-inferiority to current clinical standards for sensitivities at individual test locations, glaucoma staging using Medicare definitions and an exceptionally high correlation of 0.94 in mean deviation.1 These results underscore the accuracy and reliability of RadiusXR’s approach to visual field testing for head-mounted virtual reality perimetry.
Thomas Samuelson, MD, a distinguished ophthalmologist at Minnesota Eye Consultants in Minneapolis, says, “This technology can potentially revolutionize how we diagnose and manage ocular conditions, ultimately improving patient outcomes and quality of life.”
In July 2023, Radius XR announced it entered into a collaboration and marketing agreement with Glaukos Corporation, a leading ophthalmic pharmaceutical and medical technology company, whereby Glaukos became the exclusive sales agent to market, promote, and solicit orders for RadiusXR in the U.S. Radius continues to lead development and commercialization efforts for RadiusXR.
1 Chris Bradley, Iqbal Ike K. Ahmed, Thomas W. Samuelson, Michael Chaglasian, Howard Barnebey, Nathan Radcliffe, Jason Bacharach; Validation of a Wearable Virtual Reality Perimeter for Glaucoma Staging, The NOVA Trial: Novel Virtual Reality Field Assessment. Trans. Vis. Sci. Tech. 2024;13(3):10.
The complete details of the NOVA Clinical Trial are available here.
For more information about RadiusXR and its advanced technologies, please visit radiusxr.com.